OxStem, the University of Oxford’s regenerative drug discovery spin-off, has hired Georg Terstappen as chief scientific officer (CSO). Terstappen joins OxStem from GlaxoSmithKline’s research and development centre in Shanghai, where he served as head of platform technologies and science with responsibility for preclinical drug development. As OxStem CSO, he will head up development work across the company’s portfolio of Two programmes, which focus on stimulating progenitor and stem cell repair mechanisms within the body.
OxStem, the University of Oxford’s regenerative drug discovery spin-off, has hired Georg Terstappen as chief scientific officer (CSO). Terstappen joins OxStem from GlaxoSmithKline’s research and development centre in Shanghai, where he served as head of platform technologies and science with responsibility for preclinical drug development. As OxStem CSO, he will head up development work across the company’s portfolio of six programmes, which focus on stimulating progenitor and stem cell repair mechanisms within the body.